Arrowhead Pharmaceuticals (ARWR) Non Operating Investment Income (2011)
Arrowhead Pharmaceuticals' (ARWR) quarterly Non Operating Investment Income came in at -$58091.0 in Q4 2011, up 52.67% on a QoQ basis from -$122733.0 in Q3 2011.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Non Operating Investment Income (2011) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 1 years of Non Operating Investment Income data on file, last reported at -$58091.0 in Q4 2011.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$58091.0 in Q4 2011, while the trailing twelve-month figure through Sep 2012 was -$58091.0 (changed N/A YoY) and the FY2012 annual result came in at -$58091.0, up 77.76% from the prior year.
- Non Operating Investment Income grew to -$58091.0 in Q4 2011, from -$122733.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $359920.0 in Q1 2011 to a low of -$498406.0 in Q2 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2011 | -58,091.00 |
| Sep 30, 2011 | -122,733.00 |
| Jun 30, 2011 | -498,406.00 |
| Mar 31, 2011 | 359,920.00 |